Header Image

Latest News

Latest News

Filter Releases
 
Latest News
Date Title and Summary View
Jun 13, 2017
RESEARCH TRIANGLE PARK, N.C., June 13, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the JMP Securities 2017 Life Sciences Conference in New York on Wednesday, June 21, 2017 ...
Jun 5, 2017
RESEARCH TRIANGLE PARK, N.C., June 05, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for a pediatric indication of RAPIVAB® (peramivir injection), which  was submitted in March 2017. Th...
May 31, 2017
RESEARCH TRIANGLE PARK, N.C., May 31, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Jefferies 2017 Global Healthcare Conference in New York on Tuesday, June 6, 2017 at 10...
May 30, 2017
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the appointment of Robert A. Ingram as Chairman of its Board of Directors. Following the Company's annual meeting on May 24, 2017, Robert A. Ingram will serve as Chairman of the Board of Directors and George B. Abercrombie w...
May 25, 2017
RESEARCH TRIANGLE PARK, N.C., May 25, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and ...
May 9, 2017
RESEARCH TRIANGLE PARK, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 16, ...
May 4, 2017
RESEARCH TRIANGLE PARK, N.C., May 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2017. "We have completed enrollment in Part 1 and 2 of the APeX-1 Phase 2 clinical trial of BCX7353 for prevention of angioedema attacks and will report top-line d...
Apr 24, 2017
RESEARCH TRIANGLE PARK, N.C., April 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2017 financial results will be reported on Thursday, May 4th, 2017.  BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an up...
Apr 12, 2017
RESEARCH TRIANGLE PARK, N.C., April 12, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today plans to explore a new oral liquid formulation of BCX7353 for the treatment of acute attacks in patients with here...
Apr 3, 2017
RESEARCH TRIANGLE PARK, N.C., April 03, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment of relapsed/refractory PTCL (Peripheral T-Cell Lymphoma) by the Ministry of Health, Labor and Welfare in Jap...
Mar 29, 2017
RESEARCH TRIANGLE PARK, N.C., March 29, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the 16th Annual Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 8:40 AM Eastern ...
Mar 9, 2017
RESEARCH TRIANGLE PARK, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the pricing of an underwritten public offering of 5,294,118 shares of its common stock, offered at a price to the public of $8.50 per share.  The gross proceeds from this offering to BioCryst are expected to be $45.0 milli...
Mar 8, 2017
RESEARCH TRIANGLE PARK, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it is offering to sell $45.0 million of its common stock in an underwritten public offering. A...
Feb 27, 2017
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the fourth quarter and full year ended December 31, 2016.  In a separate press release issued earlier today, BioCryst announced positive results from an interim analysis of its APeX-1 clinical trial of...
Feb 27, 2017
Reduction of 63% in overall attack rate in HAE patients with severe disease (p=0.006) RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from an interim analysis of its Phase 2 APeX-1 trial in hereditary angioedema (HAE). APeX-1 is a dose ranging trial designe...
Page:
...
Next Last